NASDAQ · SDGRHealthcarePharmaceuticals

Schrodinger financials

$30.33+2.81%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$255.9M$207.5M$216.7M$181.0M$137.9M$108.1M
Gross profit$142.6M$132.1M$140.7M$101.0M$65.6M$63.5M
Gross margin55.7%63.6%64.9%55.8%47.6%58.7%
Operating income-$166.9M-$209.3M-$177.4M-$146.8M-$111.4M-$60.9M
Net income-$103.3M-$187.1M$40.7M-$149.2M-$100.4M-$24.5M
Net margin−40.4%−90.2%18.8%−82.4%−72.8%−22.6%
Diluted EPS$-1.41$-2.57$0.54$-2.10$-1.42$-0.41
EBITDA-$160.9M-$203.1M-$171.9M-$142.5M-$108.6M-$51.9M
Operating cash flow$13.9M-$157.4M-$136.7M-$119.7M-$70.7M$16.8M
Free cash flow$12.5M-$164.7M-$150.1M-$127.7M-$77.8M$14.2M
Diluted shares73.4M72.7M75.0M71.2M70.6M60.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$230.5M$147.3M$155.3M$90.5M$120.3M$202.3M
Short-term investments$164.9M$204.8M$307.7M$360.6M$456.2M$440.4M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$726.2M$823.2M$803.0M$688.6M$756.5M$746.3M
Total liabilities$362.1M$401.8M$254.4M$240.7M$199.4M$122.2M
Shareholders' equity$364.1M$421.4M$548.6M$447.9M$557.1M$624.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology